Urszula Masiukiewicz

6.5k total citations · 3 hit papers
21 papers, 4.2k citations indexed

About

Urszula Masiukiewicz is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Urszula Masiukiewicz has authored 21 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 12 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Oncology. Recurrent topics in Urszula Masiukiewicz's work include Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (8 papers) and Bone health and treatments (6 papers). Urszula Masiukiewicz is often cited by papers focused on Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (8 papers) and Bone health and treatments (6 papers). Urszula Masiukiewicz collaborates with scholars based in United States, Sweden and Canada. Urszula Masiukiewicz's co-authors include Giancarlo Agnelli, Margot Johnson, Raphael Pak, Madelyn Curto, Gary E. Raskob, John R. Thompson, Alexander Gallus, Jeffrey I. Weitz, Harry R. Büller and Alexander T. Cohen and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Urszula Masiukiewicz

20 papers receiving 4.1k citations

Hit Papers

Oral Apixaban for the Tre... 2013 2026 2017 2021 2013 2020 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Oral Apixaban for the Treatment of Acute Venous Thromboembolism
    2013 1.7k citations Giancarlo Agnelli, Harry R. Büller et al. New England Journal of Medicine profile →
  2. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
    2020 1.0k citations Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine profile →
  3. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
    2020 708 citations Darren K. McGuire, Weichung Shih et al. JAMA Cardiology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Urszula Masiukiewicz United States 14 2.0k 1.9k 1.5k 1.1k 905 21 4.2k
David Baanstra United States 8 1.2k 0.6× 2.5k 1.3× 2.3k 1.6× 828 0.8× 422 0.5× 9 3.9k
Jean‐Philippe Collet France 36 717 0.4× 3.9k 2.1× 987 0.7× 2.2k 2.0× 209 0.2× 124 5.1k
Farzin Beygui France 32 855 0.4× 4.0k 2.1× 924 0.6× 2.2k 2.1× 176 0.2× 155 5.2k
Janet Schnee United States 21 666 0.3× 4.8k 2.5× 4.0k 2.7× 1.1k 1.1× 455 0.5× 45 6.1k
Jyotsna Garg United States 14 2.0k 1.0× 7.0k 3.7× 3.2k 2.1× 1.2k 1.2× 773 0.9× 23 10.0k
Francesca Lawson United States 13 1.9k 0.9× 738 0.4× 431 0.3× 1.2k 1.1× 808 0.9× 19 3.2k
W. Schuyler Jones United States 38 648 0.3× 1.9k 1.0× 616 0.4× 2.9k 2.7× 353 0.4× 217 4.6k
Brendan M. Everett United States 36 1.6k 0.8× 2.2k 1.2× 123 0.1× 1.6k 1.6× 931 1.0× 91 5.2k
Leanne Dyal Canada 15 1.3k 0.7× 1.9k 1.0× 182 0.1× 659 0.6× 326 0.4× 24 3.2k
Atsushi Hirayama Japan 39 503 0.2× 3.4k 1.8× 396 0.3× 2.6k 2.5× 399 0.4× 354 6.0k

Countries citing papers authored by Urszula Masiukiewicz

Since Specialization
Citations

This map shows the geographic impact of Urszula Masiukiewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Urszula Masiukiewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Urszula Masiukiewicz more than expected).

Fields of papers citing papers by Urszula Masiukiewicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Urszula Masiukiewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Urszula Masiukiewicz. The network helps show where Urszula Masiukiewicz may publish in the future.

Co-authorship network of co-authors of Urszula Masiukiewicz

This figure shows the co-authorship network connecting the top 25 collaborators of Urszula Masiukiewicz. A scholar is included among the top collaborators of Urszula Masiukiewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Urszula Masiukiewicz. Urszula Masiukiewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pandey, Ambarish, Ahmed A. Kolkailah, Robert Frederich, et al.. (2025). Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial. European Journal of Heart Failure. 27(3). 521–526. 1 indexed citations
2.
Dagogo‐Jack, Samuel, Robert Frederich, Jie Liu, et al.. (2023). Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV. The Journal of Clinical Endocrinology & Metabolism. 108(8). 2042–2051. 2 indexed citations
3.
Inzucchi, Silvio E., Ian J. Neeland, James P. Mancuso, et al.. (2022). Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep And Breathing. 27(2). 669–672. 27 indexed citations
4.
Dagogo‐Jack, Samuel, Robert Frederich, B Charbonnel, et al.. (2021). 785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV. Diabetes. 70(Supplement_1). 1 indexed citations
5.
Cosentino, Francesco, Christopher P. Cannon, David Z.I. Cherney, et al.. (2020). Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation. 142(23). 2205–2215. 175 indexed citations
6.
McGuire, Darren K., Weichung Shih, Francesco Cosentino, et al.. (2020). Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology. 6(2). 148–148. 708 indexed citations breakdown →
7.
Cannon, Christopher P., Richard E. Pratley, Samuel Dagogo‐Jack, et al.. (2020). Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine. 383(15). 1425–1435. 1011 indexed citations breakdown →
8.
Cannon, Christopher P., Darren K. McGuire, Richard E. Pratley, et al.. (2018). DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV). Journal of the American College of Cardiology. 71(11). A1825–A1825. 55 indexed citations
9.
Cannon, Christopher P., Darren K. McGuire, Richard E. Pratley, et al.. (2018). Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal. 206. 11–23. 160 indexed citations
10.
Hickman, Mary A., Robert Frederich, Shrita M. Patel, et al.. (2018). Evaluation of Fractures, Bone Mineral Density (BMD), and Bone Biomarkers in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin. Diabetes. 67(Supplement_1). 4 indexed citations
11.
Agnelli, Giancarlo, Harry R. Büller, Alexander T. Cohen, et al.. (2013). Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine. 369(9). 799–808. 1657 indexed citations breakdown →
12.
Masiukiewicz, Urszula. (2002). Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal of Clinical Endocrinology & Metabolism. 87(6). 2892–2898. 3 indexed citations
13.
Masiukiewicz, Urszula, Maryann Mitnick, Barbara Gulanski, & Karl Insogna. (2002). Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal of Clinical Endocrinology & Metabolism. 87(6). 2892–2898. 20 indexed citations
14.
Insogna, Karl, et al.. (2002). Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.. PubMed. 17 Suppl 2. N108–16. 10 indexed citations
15.
Mitnick, Mary Ann, Andrew Grey, Urszula Masiukiewicz, et al.. (2001). Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. American Journal of Physiology-Endocrinology and Metabolism. 280(3). E405–E412. 65 indexed citations
16.
Masiukiewicz, Urszula, Maryann Mitnick, Andrew Grey, & Karl Insogna. (2000). Estrogen Modulates Parathyroid Hormone-Induced Interleukin-6 Production in Vivo and in Vitro*. Endocrinology. 141(7). 2526–2531. 36 indexed citations
17.
Masiukiewicz, Urszula & Gerard N. Burrow. (1999). Hyperthyroidism in Pregnancy: Diagnosis and Treatment. Thyroid. 9(7). 647–652. 43 indexed citations
18.
Masiukiewicz, Urszula, Inaam A. Nakchbandi, Andrew F. Stewart, & Silvio E. Inzucchi. (1999). Papillary Thyroid Carcinoma Metastatic to the Pituitary Gland. Thyroid. 9(10). 1023–1027. 44 indexed citations
19.
Grey, Andrew, Maryann Mitnick, Urszula Masiukiewicz, et al.. (1999). A Role for Interleukin-6 in Parathyroid Hormone-Induced Bone Resorption in Vivo1. Endocrinology. 140(10). 4683–4690. 113 indexed citations
20.
Masiukiewicz, Urszula & Karl Insogna. (1998). The role of parathyroid hormone in the pathogenesis, prevention and treatment of postmenopausal osteoporosis. Aging Clinical and Experimental Research. 10(3). 232–239. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Baanstra Breakdown of academic impact, for papers by Jean‐Philippe Collet Breakdown of academic impact, for papers by Farzin Beygui Breakdown of academic impact, for papers by Janet Schnee Breakdown of academic impact, for papers by Jyotsna Garg Breakdown of academic impact, for papers by Francesca Lawson Breakdown of academic impact, for papers by W. Schuyler Jones Breakdown of academic impact, for papers by Brendan M. Everett Breakdown of academic impact, for papers by Leanne Dyal Breakdown of academic impact, for papers by Atsushi Hirayama
Rankless by CCL
2026